Allergic rhinitis (AR) is the most common chronic disease in the pediatric population and its prevalence is increasing. AR can significantly impact a child's health. It causes uncomfortable symptoms, impairs quality of life, and can predispose to the development of comorbidities such as asthma. Although allergen avoidance is the first step in AR management, it often is impractical. Fortunately, there are a number of pharmacologic agents available for the treatment of AR. When choosing a medication, attention should be paid to the substance's risk/benefit ratio. First-line therapy consists of second-generation antihistamines, which lack many of the unwanted side effects caused by first-generation compounds, and intranasal corticosteroids, which are the preferred agents for children with persistent symptoms. Other pharmacologic options include decongestants, leukotriene-receptor antagonists, and intranasal cromolyn sodium. Allergen immunotherapy can be a valuable adjunctive modality. Issues of compliance and convenience also are important considerations.
Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.